Myeloma: update on supportive care strategies

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Multiple myeloma (MM) remains an incurable hematologic malignancy despite treatment innovations.
• The contribution of tumor-destroying therapies versus complication-ameliorating therapies to survival improvements is debated.
• Supportive care in hematologic malignancies has advanced with new antibiotics, antifungals, and growth factors.

Purpose of the Study:

• To evaluate the role of supportive therapy in the overall management of multiple myeloma.
• To highlight the evolution and specific adjuvant therapies in multiple myeloma supportive care.

Main Methods:

• Review of general supportive measures in hematologic malignancies.
• Analysis of specific adjuvant therapies introduced for multiple myeloma.
• Assessment of the impact of supportive care on patient survival and disease complications.

Main Results:

• Supportive therapy has evolved significantly, encompassing general measures and specific MM treatments.
• Adjuvant therapies like bisphosphonates and erythroid-stimulating factors are crucial in MM management.
• Progress in MM survival may be attributed to both direct anti-myeloma treatments and improved supportive care.

Conclusions:

• Supportive therapy plays a pivotal role in the comprehensive treatment strategy for multiple myeloma.
• Specific adjuvant therapies have become integral to managing MM complications and improving patient outcomes.
• Further research into optimizing supportive care is essential for enhancing the quality of life and survival for MM patients.